XML 30 R20.htm IDEA: XBRL DOCUMENT v3.19.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended
Mar. 31, 2019
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of estimated useful lives of property, plant and equipment

 

 

 

 

Production equipment

    

3 to 13 years

Office furniture and equipment

 

3 to 10 years

Buildings

 

39 years

Building improvements

 

15 years

 

Schedule of significant customers

 

 

 

 

 

 

 

 

 

 

 

Three Months
Ended

 

Three Months
Ended

 

 

    

March 31, 2019

    

March 31, 2018

    

Number of significant customers

 

 

 3

 

 

 4

 

Aggregate dollar amount of net sales to significant customers

 

$

3.9

million 

$

4.9

million

Percentage of net sales to significant customers

 

 

48.6

 

63.3

%

 

Schedule of disaggregated information of revenue recognized from contracts with customers

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the three months ended March 31, 2019:

 

    

 

 

    

Blood

    

 

 

    

 

 

    

Total

 

 

 

 

 

Collection

 

EasyPoint®

 

Other

 

Product

Geographic Segment

 

Syringes

 

Products

 

Needles

 

Products

 

Sales

U.S. sales

 

$

5,625,387

 

$

451,077

 

$

48,472

 

$

14,975

 

$

6,139,911

North and South America sales (excluding U.S.)

 

 

1,330,330

 

 

3,863

 

 

252

 

 

925

 

 

1,335,370

Other international sales

 

 

241,243

 

 

210,700

 

 

 

 

5,250

 

 

457,193

Total

 

$

7,196,960

 

$

665,640

 

$

48,724

 

$

21,150

 

$

7,932,474

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the three months ended March 31, 2018:

 

    

 

 

    

Blood

    

 

 

    

 

 

    

Total

 

 

 

 

 

Collection

 

EasyPoint®

 

Other

 

Product

Geographic Segment

 

Syringes

 

Products

 

Needles

 

Products

 

Sales

U.S. sales

 

$

6,264,189

 

$

235,085

 

$

83,285

 

$

14,421

 

$

6,596,980

North and South America sales (excluding U.S.)

 

 

1,024,204

 

 

6,055

 

 

252

 

 

900

 

 

1,031,411

Other international sales

 

 

41,300

 

 

2,760

 

 

 

 

350

 

 

44,410

Total

 

$

7,329,693

 

$

243,900

 

$

83,537

 

$

15,671

 

$

7,672,801

 

Schedule of earnings per share

 

 

 

 

 

 

 

 

 

 

 

Three Months
Ended

 

Three Months
Ended

 

    

March 31, 2019

    

March 31, 2018

Net loss

 

$

(129,221)

 

$

(179,284)

Preferred stock dividend requirements

 

 

(176,249)

 

 

(176,249)

Loss applicable to common shareholders

 

$

(305,470)

 

$

(355,533)

Weighted average common shares outstanding

 

 

32,666,454

 

 

32,666,454

Weighted average common and common equivalent shares outstanding — assuming dilution

 

 

32,666,454

 

 

32,666,454

Basic loss per share

 

$

(0.01)

 

$

(0.01)

Diluted loss per share

 

$

(0.01)

 

$

(0.01)

 

Summary of impact on adoption of ASU 2016-02 to previously reported results relating to balance sheet

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

New Lease

 

 

 

 

 

As Previously

 

Standard

 

As

Balance Sheet as of December 31, 2018

    

Reported

    

Adjustment

    

Restated

Other assets

 

$

2,849

 

$

163,007

 

$

165,856

Other current liabilities

 

 

1,387,287

 

 

80,648

 

 

1,467,935

Other long-term liabilities

 

 

 —

 

 

82,359

 

 

82,359